On October 7, Natera fell 3.73% in regular trading, trading at $390.55/share, with turnover of $345 million.

The decline reflects profit-taking pressure following gains tied to the announcement of a phase 3 breast cancer trial, while a new study launch for melanoma did not sustain positive momentum. Natera and NYU Langone Health initiated a trial using Signatera to detect persistent molecular residual disease before radiographic progression, guiding treatment escalation for advanced or metastatic melanoma. The primary endpoint is progression-free survival.

Earlier this week, Natera and Alliance Foundation Trials launched a phase 3 trial combining giredestrant with Signatera monitoring for ER-positive/HER2-negative breast cancer, expecting over 2,000 patients. Despite positive clinical catalysts and recent analyst target increases, the stock faced selling after recent upside.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)